Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.

Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company ...

Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday. Michael Cherny has ...

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS. Read why I ...

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S.

Quest Diagnostics (NYSE:DGX) announced on Wednesday that it will roll out a rapid molecular lab test to detect the avian ...

Quest Diagnostics reported strong third-quarter earnings driven by acquisitions, with revenue surpassing expectations, though ...

The not-for-profit charitable health group of the United Methodist Church will transition its outreach testing to the ...

Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, ...

Q3 2024 Earnings Call Transcript October 22, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is ...

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

U.S. stocks were lower, with the Dow Jones index falling around 50 points on Tuesday. Quest Diagnostics posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.